Wilmington Healthcare-pharmaphorum conference: England’s NHS is moving towards integrated care, and long-term outcomes-based contracts for medicines could become the norm
The EMA's human medicines committee has recommended against approval of Eisai and Biogen's Alzheimer's disease therapy Leqembi, after regulators in the US, China and Japan gave a green ligh